Ramipril
Ramipril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for ramipril capsules (a generic product), lists three uses: treating high blood pressure, reducing the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years or older who are at high risk, and treating stable patients who show clinical signs of congestive heart failure after a myocardial infarction. The label read is a generic product label; the brand names for this substance are recorded as aliases.
Also called Altace
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 35296; UNII L35JN3I7SJ. UNII L35JN3I7SJ is the UNII of the substance as the label names it. MeSH descriptor D017257 is Ramipril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Lupin Pharmaceuticals, Inc. label for ramipril capsules, application ANDA077626, effective 2026-08-24 in openFDA; Drugs@FDA lists the application's sponsor as LUPIN. The brand label for Altace (NDA019901, listed as discontinued in Drugs@FDA) and other generic ramipril labels were not used. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 1 | 0 | 1 |
| Phase 3 | 1 | 1 | 1 | 3 |
| Phase 4 | 0 | 1 | 0 | 1 |
| All phases | 1 | 3 | 1 | 5 |
Conditions these trials study
- Heart attack (myocardial infarction)
- Hypertension (high blood pressure)
- Diabetes mellitus
- Heart failure
- Non-ST-elevation heart attack (NSTEMI)
- ST-elevation heart attack (STEMI)
- Type 2 diabetes
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The cardiovascular risk reduction indication names patients 55 years or older at high risk; the other indications do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- 55 years or older for the risk reduction indication, as the passage read states; not stated for the other indications
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients 55 years or older at high risk of developing a major cardiovascular event
- Stable patients with clinical signs of congestive heart failure after myocardial infarction
- Excluded
- None stated
The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.
Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-08-24
- Source state
- Current
- Version fingerprint
24f903fd224e0ef770232bcf983d79d62f096b11a99cc6e76477543c06681017- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260824.
- Retrieved
- Source effective date
- 2026-08-24
- Source state
- Current
- Version fingerprint
24f903fd224e0ef770232bcf983d79d62f096b11a99cc6e76477543c06681017- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for application ANDA077626 (RAMIPRIL, sponsor LUPIN): product and sponsor
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application ANDA077626, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
bf76a68dfcbe9d23ddaf931da089463694952084b2de52dda2c12a03a9db90a6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ALTACE
No label from the application holder was found in the openFDA label dataset for application NDA019901. This page does not show another labeler's label in its place.
ALTACE
No label from the application holder was found in the openFDA label dataset for application NDA022021. This page does not show another labeler's label in its place.
VOSTALLY
No label from the application holder was found in the openFDA label dataset for application NDA219757. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists clinical signs of congestive heart failure after a myocardial infarction in stable patients as an indication: Heart failure
Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk as an indication: Stroke
Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction
The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 3
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 5
Record details
- Record id
cardio:ramipril- Content hash
4fb1c6ce9447bbdd019c85d09958e6144a3916bcdda695d580320c32966ae7f7